EOS imaging obtains regulatory authorization to sell its products in Taiwan EOS® can now be deployed in Taiwan, further advancing the Company’s expansion into the Asia-Pacific region Business Wire PARIS -- April 14, 2014 Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766-EOSI), the pioneer in orthopaedic 2D/3D imaging, eligible for PEA-PME, today announced that Taiwanese regulatory authorities have authorized the sale of the EOS® imaging system. The EOS imaging system offers ultra-low radiation dose 2D and 3D X-ray imaging of the full body in a natural weight-bearing position. It has already been approved for sale in more than 30 countries. Approval from Taiwanese regulators represents an important milestone as the Company continues its commercial development efforts in the Asia-Pacific region. EOS has also signed a distribution agreement with the Taiwanese company Unison Co. Ltd. to sell EOS imaging systems in the country. Marie Meynadier, CEO of EOS imaging, noted: “the regulatory authorization to deploy our system in Taiwan reflects the continued momentum of our commercial development in the Asia-Pacific region. Together with a strong partnership with our local distributor in Taiwan, this new step now allows us to deploy EOS in this significant Asian market.” About EOS imaging: EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. AsofDecember31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com EOS imaging is listed on Compartment C of Euronext Paris ISIN: FR0011191766 – Ticker: EOSI Next press release: revenue for the 1^st half of 2014, on July 22, 2014 (after market). Contact: EOS imaging Anne Renevot, +33 (0)1 55 25 61 24 CFO email@example.com or NewCap. Financial communication and investor relations Sophie Boulila / Pierre Laurent, +33 (0)1 44 71 94 91 firstname.lastname@example.org or The Ruth Group (US) Press relations Melanie Sollid-Penton, 646-536-7023 email@example.com
EOS imaging obtains regulatory authorization to sell its products in Taiwan
Press spacebar to pause and continue. Press esc to stop.